Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
EXAS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$40.62 - $79.62
Previous CloseN/A
Volume846.89K
Average Volume (3M)2.17M
Market Cap
$10.36B
Enterprise Value$14.35B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Feb 25, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding185,076,300
10 Day Avg. Volume3,198,124
30 Day Avg. Volume2,173,243
Standard Deviation0.16
R-Squared0.17
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.85
Price to Cash Flow (P/CF)18.70
P/FCF Ratio33.50
Enterprise Value/Market Cap1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.77
Enterprise Value/Ebitda546.06
Forecast
1Y Price Target
$73.62Price Target Upside31.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Exact Sciences News
PremiumCompany Announcements
Exact Sciences Boosts Finances and Plans New Launches
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityEXAS benefits from care gap, 45-49-year-olds expansion presenting a 20 million patient opportunity, and rescreens.
Product Launch And PricingEXAS secures a price increase of approximately $592 per test for Cologuard Plus, representing a 16% rise compared to its first generation Cologuard test.
Revenue GrowthScreening revenues beat expectations, growing 13.5% and 3% above analysts and market consensus.
Bears Say
Guidance ReductionThe company's third-quarter results fell short of expectations, leading to a reduction in guidance for both Cologuard and Oncotype businesses.
Sales Force ChallengesThe screening segment has suffered due to sales force challenges, such as insufficient follow-up between sales and new prescribers, misaligned incentives, and poor division of sales territories.
Stock PerformanceEXAS' stock is indicating down 30%, and significant cuts to numbers were made, reducing the price target from $82 to $65.
---
Ownership Overview
1.02% Insiders
45.08% Mutual Funds
1.00% Other Institutional Investors
37.99% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $40.62 and its highest was $79.62 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Exact Sciences Corp.’s market cap is $10.36B.
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is Feb 25, 2025 which is in 19 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on Nov 05, 2024. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.196 by -$0.014.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -0.32.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 185,076,300 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.196. Following the earnings report the stock price went down -23.479%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Currently, no hedge funds are holding shares in EXAS
---
Exact Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$73.62 (31.98% Upside)
$73.62 (31.98% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 267.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.83%
12-Months-Change
Fundamentals
Return on Equity
-6.67%
Trailing 12-Months
Asset Growth
5.10%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
---
EXAS Company Deck
---
EXAS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth, profitability, and operational achievements, including the FDA approval of Cologuard Plus. However, execution challenges, particularly in Cologuard order growth, hurricane impacts, and transitional issues in Precision Oncology, weighed on the company's outlook for the rest of the year.Read More>---
EXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
---
EXAS Stock 12 Month Forecast
Average Price Target
$73.62
▲(31.98% Upside)
Technical Analysis
Best Analysts Covering EXAS
1 Year
1 Year Success Rate
15/21 ratings generated profit
1 Year Average Return
+33.12%
reiterated a buy rating 4 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +33.12% per trade.
---